Frontier IP Group Plc (FIPP.L) Announced with respect to the announcement from portfolio company Exscientia, a world leader in
artificial intelligence (AI) drug discovery, that it has achieved its first major milestone in its collaboration
with GSK. Exscientia has delivered a lead molecule targeting chronic obstructive pulmonary disease
(COPD), a progressive lung disease thought to affect 384 million people globally. The company holds
a 3.32% stake in Exscientia.